Cimzia Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The cimzia market size has grown rapidly in recent years. It will grow from $3.57 million in 2025 to $4.19 million in 2026 at a compound annual growth rate (CAGR) of 17.6%. The growth in the historic period can be attributed to approval of tnf inhibitors, rising autoimmune disease prevalence, limited effectiveness of conventional therapies, specialist prescribing patterns, hospital based biologic adoption.

The cimzia market size is expected to see rapid growth in the next few years. It will grow to $7.94 million in 2030 at a compound annual growth rate (CAGR) of 17.3%. The growth in the forecast period can be attributed to growth of biologic treatment guidelines, increasing diagnosis rates of autoimmune disorders, expansion of biosimilar competition, rising patient preference for targeted therapies, improved reimbursement coverage. Major trends in the forecast period include growing adoption of tnf inhibitor biologics, expansion of use in multiple autoimmune diseases, shift toward long term disease control therapies, increased acceptance of self injected biologics, rising focus on patient quality of life.

The increasing prevalence of rheumatoid arthritis is anticipated to drive the growth of the Cimzia market in the coming years. Rheumatoid arthritis (RA) is a long-term autoimmune condition in which the immune system mistakenly attacks healthy joint tissues, resulting in inflammation, pain, and joint swelling. The rising prevalence of RA is linked to factors such as an aging population, growing genetic susceptibility, environmental influences including smoking and pollution, as well as greater awareness and improved diagnostic capabilities. Cimzia plays a key role in addressing the rising burden of rheumatoid arthritis by offering targeted therapy that reduces inflammation, alleviates symptoms, improves patient quality of life, and supports more effective disease management. For instance, in February 2024, according to Arthritis WA, an Australia-based organization, RA cases are projected to reach approximately 212,136 men and 362,137 women by 2025, and are expected to increase further to about 280,040 men and 479,828 women by 2040. Therefore, the growing prevalence of rheumatoid arthritis is fueling the expansion of the Cimzia market.

The growing aging population is expected to further support the growth of the Cimzia market going forward. An aging population refers to an increasing share of older individuals in society, driven by longer life expectancy and declining birth rates. The expansion of the aging population is largely due to advancements in healthcare that have contributed to extended lifespans. Cimzia is commonly used among older adults to manage chronic inflammatory conditions such as arthritis, helping to reduce pain and improve mobility. For instance, in January 2024, according to the Population Reference Bureau, a US-based non-profit organization, the population of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, representing a 47% rise. Consequently, this age group’s share of the total U.S. population is expected to grow from 17% to 23% during this period. As a result, the rising aging population is contributing to the growth of the Cimzia market.

Leading companies operating in the Cimzia market are concentrating on the development of innovative treatment approaches, including autoimmune therapy solutions, to broaden treatment options for patients with non-radiographic axial spondyloarthritis and address unmet needs in autoimmune disease management. Autoimmune therapy solutions involve treatments aimed at restoring immune system balance and tolerance, often through targeted immunotherapies and advanced cellular approaches. For example, in July 2024, UCB, a Belgium-based biopharmaceutical company, announced the expansion of CIMZIA (certolizumab pegol) as a treatment option for patients with non-radiographic axial spondyloarthritis (nr-axSpA). This expansion is intended to offer an advanced therapeutic option for patients who continue to experience symptoms despite not yet showing radiographic evidence of the disease. CIMZIA is the first and only biologic approved by the FDA for nr-axSpA, underscoring its distinctive position within the autoimmune treatment landscape. This approval provides an important alternative to conventional therapies, helping patients achieve improved symptom control and enhanced quality of life.

Major companies operating in the cimzia market are UCB SA.

North America was the largest region in the cimzia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cimzia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cimzia market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the cimzia market by raising costs for imported biologic raw materials, pegylation components, and cold-chain distribution systems. These cost pressures are more visible in hospital and specialty pharmacy distribution channels. North america and europe experience margin and pricing challenges due to biologics import dependence. However, tariffs are accelerating investments in regional biologics manufacturing and fill-finish operations. This supports supply chain resilience and long-term cost stabilization.

The cimzia market research report is one of a series of new reports that provides cimzia market statistics, including cimzia industry global market size, regional shares, competitors with a cimzia market share, detailed cimzia market segments, market trends and opportunities, and any further data you may need to thrive in the cimzia industry. This cimzia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cimzia (certolizumab pegol) is a PEGylated monoclonal antibody that targets tumor necrosis factor (TNF) and is used to reduce inflammation and prevent immune system-related damage in specific autoimmune disorders. It is prescribed for the treatment of moderate to severe rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.

The primary types of Cimzia include biologics and biosimilars, which are developed to meet the needs of both adult and pediatric patients. Cimzia is supplied through multiple distribution channels, including hospital pharmacies, drug stores, retail pharmacies, and online pharmacies. Its use covers the management of conditions such as Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, active psoriatic arthritis, axial spondyloarthritis, and plaque psoriasis.

The cimzia market consists of sales of injectable formulations, pre-filled syringes, auto-injectors, and IV infusions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.